<DOC>
	<DOCNO>NCT02176525</DOCNO>
	<brief_summary>The purpose study investigate antiviral activity , safety pharmacokinetics 5 day monotherapy BI 207127 HCV genotype 1 ( GT1 ) infect patient . Both treatment-naïve patient patient previously treat peginterferon ribavirin include . In addition , effect study medication examine group patient liver cirrhosis .</brief_summary>
	<brief_title>Multiple Oral Doses BI 207127 NA Treatment naïve Treatment-experienced Hepatitis C Virus ( HCV ) -Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Adults 18 70 year Male OR female document hysterectomy OR menopausal female last menstrual period least 12 month prior screen Written informed consent consistent International Conference Harmonization/Good Clinical Practice local legislation give prior study procedure Chronic HCV infection demonstrate positive HCV immunoglobulin G Antibody HCV genotype 1 confirmed central laboratory test Visit 2 For noncirrhotic cohort : Liver biopsy obtain within last 36 month consistent HCV infection show minimal mild liver fibrosis without cirrhosis ( Ishak Metavir grade ≤ 2 ) . For cirrhotic cohort , previous liver biopsy Fibroscan consistent liver cirrhosis perform time screen HCV RNA load &gt; 100,000 IU RNA per ml serum screen All fertile male willing use adequate form contraception ( condom , sterilisation least 6 month post operation ) case partner childbearing potential use adequate form contraception ( hormonal contraceptive , oral injectable/ implantable , intrauterine device ) Patients treat least one dose HCVpolymerase inhibitor acute chronic hepatitis C infection Any additional plausible cause chronic liver disease , include presence virus know suspected cause hepatitis Decompensated liver disease within past 12 month , indicate variceal bleeding , ascites , encephalopathy , Prothrombin International Normalized Ratio ( INR ) prolong &gt; 1.7 x upper limit normal ( ULN ) , serum bilirubin &gt; 2 mg/dl albumin &lt; 3.5 g/dl ( i.e . ChildPugh grade B , score &gt; 7 ) For noncirrhotic cohort : Any previous liver biopsy consistent cirrhosis . For cirrhotic cohort : Any liver biopsy fibroscan result last 2 year exclude liver cirrhosis . Positive test human immunodeficiency virus ( HIV ) hepatitis B antigen screen Current alcohol drug abuse , history , within past six ( 6 ) month . Exception : Occasional use cannabis exclusion criterion . The investigator must however instruct patient consumption cannabis allow treatment period . Any concurrent disease ( cardiovascular , pulmonary , renal , haematological , neurological , psychiatric , immunologic , metabolic endocrine dysfunction ) clinically significant base investigator 's medical assessment screening . A clinically significant disease define one opinion investigator may either put patient risk participation study may influence result study patient 's ability participate study . Exclusion also necessary preexist cardiac abnormality history . Clinically significant abnormality screen ECG , include limited QTc longer 435 msec , Pulse Rate &gt; 240 msec baseline bundle branch block pattern , necessarily nonspecific T wave abnormality History malignancy ( except previously cure squamous cell basal cell carcinoma ) Patients treat interferon ( IFN ) ( approve investigational ) PegIFN and/or Ribavirin within 3 month prior screen Planned concurrent usage pharmacological therapy include antiviral therapy vaccination 7 day treatment treatment Usage investigational drug within thirty ( 30 ) day prior enrolment 5 halflives , whichever longer ; plan usage investigational drug course current study Known hypersensitivity drug excipients Patients one follow laboratory value screen : Alanine transaminase ( ALT ) &gt; 3x ULN , local lab Aspartate aminotransferase ( AST ) &gt; 3x ULN , local lab Total bilirubin &gt; 1.5x ULN , local lab , unless predominantly conjugate reflect Gilbert 's disease Alkaline phosphatase &gt; 1.5x ULN , local lab Prothrombin time ( INR ) &gt; 1.5x ULN , central lab Creatinine &gt; 1x ULN , local lab Urine protein / creatinine ratio &gt; 0.3 g protein / g creatinine , central lab Alpha1microglobulin / creatinine urine &gt; 1x ULN , central lab Platelet count &lt; 100,000 / mm3 , central lab White Blood cell count &lt; 2000 cells/mm3 , central lab Absolute neutrophile count &lt; 1500 cell , central lab Hemoglobin &lt; 12 g/dL , central lab For patient liver cirrhosis : ALT &gt; 5x ULN , local lab AST &gt; 5x ULN , local lab Platelet count &lt; 70,000 / mm3 , central lab Patients clinically significant laboratory abnormality base investigator 's medical assessment screen Positive urine test drug abuse screen Prior randomisation trial Inability comply protocol Patients ongoing historical photosensitivity recurrent rash Alpha fetoprotein value ( AFP ) &gt; 100 ng/ml ; AFP &gt; 20 ≤ 100 ng/ml , patient include liver cancer exclude current imaging study ( i.e . ultrasound , computer tomography scan magnetic resonance imaging )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>